<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The effects of combinations of <z:chebi fb="0" ids="4653">dipyridamole</z:chebi>, an effective blocker of the salvage pathway of DNA synthesis, and 8 types of anti-<z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> drugs on the growth of human T, B and <z:mpath ids='MPATH_342'>myeloid leukaemia</z:mpath>/<z:hpo ids='HP_0002665'>lymphoma</z:hpo> cell lines in vitro were examined </plain></SENT>
<SENT sid="1" pm="."><plain>In combinations, <z:chebi fb="0" ids="4653">dipyridamole</z:chebi> and <z:chebi fb="0" ids="28445">vincristine</z:chebi> (VCR), and <z:chebi fb="0" ids="4653">dipyridamole</z:chebi> and <z:chebi fb="0" ids="36373">vindesine</z:chebi> had synergistic inhibitory effects </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="0" ids="4653">Dipyridamole</z:chebi> reduced the efflux of VCR from cells and enhanced their VCR accumulation in a dose-dependent manner at concentrations of up to 10 microM in the lymphoid cell lines, MOLT-3 and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>-TH, and of up to at least 20 microM in the myeloid cell line, ML-1 </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="0" ids="4653">Dipyridamole</z:chebi> also enhanced the accumulation of VCR in PHA-stimulated and un-stimulated lymphocytes of <z:mpath ids='MPATH_458'>normal</z:mpath> donors, but efflux of VCR was more rapid from <z:mpath ids='MPATH_458'>normal</z:mpath> lymphocytes than from cultured cell lines </plain></SENT>
<SENT sid="4" pm="."><plain>It is proposed that combination therapy with <z:chebi fb="0" ids="4653">dipyridamole</z:chebi> plus VCR should be effective in the treatment of <z:mpath ids='MPATH_336'>leukaemia</z:mpath> and <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
</text></document>